AzTrials
AzTrials

Vaccine ReactionNOVACNCT03176719

Non-specific Effects of Vaccination on Mortality and Morbidity

An observational study of Vaccine Reaction and Anemia, run by Radboud University Medical Center at 1 site in Burkina Faso.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

It has long been recognized that the positive effects of vaccination on childhood mortality cannot be solely attributed to a decline in the disease targeted by the vaccine. These so-called non-specific effects of vaccination have so far mostly been linked to mortality. Read more about this study

Who is it for?
Ages 1 year and olderHealthy volunteers can take part
Conditions the study is for
Vaccine Reaction, Anemia, Malaria,Falciparum
What is being tested?
Venipuncture
How many people
1,005 participants
Where
1 siteBurkina Faso
Study dates
17 Jun 2017to 31 Dec 2018
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 year and older
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: A total of 5 groups will be selected. Each age group will consist of 220 participant (including 20% for potential non response). The survey will be conducted among 24 villages. Demographic age distribution is comparable for each of the villages. In order to prevent bias, a proportionate number of participants will be selected from each village based on its total population. Participants will then be randomly selected from each sample stratum using systematic selection.

Who may be able to join

  • Healthy participants currently living in the Nanoro HDSS area, born before May 2016.

Who cannot join

  • Current febrile illness,
  • Current chronic illnesses, HIV, TB, renal failure, cardiac disease (if known)
  • Patients that have participated in the RTSS vaccination trial from Glaxo-Smith-Kline at the same inclusion site.

Trial locations and contacts

1 site in 1 country.

Burkina Faso1 site
  • Clinical Research Unit of Nanoro

    Nanoro, Boulkiemedé

Other trials in Burkina Faso

About this study

Official title: The Non-specific Effects of Vaccination Related to Mortality and Morbidity in Nanoro Health and Demographic Surveillance System Cohort

It has long been recognized that the positive effects of vaccination on childhood mortality cannot be solely attributed to a decline in the disease targeted by the vaccine. These so-called non-specific effects of vaccination have so far mostly been linked to mortality. However, it has been suggested that non-specific effects may also effect morbidity and nutritional status. This study aims to further explore the correlation between vaccination, susceptibility to infectious diseases (particularly malaria and bacterial infections), nutritional status and immunity.

With this prospective cross sectional study among healthy individuals in rural west-Africa we aim to address several research questions at the same time. This study will assess the influence of (time-point of) vaccination on morbidity, mortality and immune status among healthy individuals in a rural sub-Saharan African setting. Secondly, to explore the prevalence of subclinical malaria, iron deficiency anemia, sickle cell anemia and thallasemia among a healthy rural sub-Saharan African population. And finally to assess normal hemocytometry values among a healthy rural sub-Saharan African population.

Read the detailed description

A cross sectional study among healthy participants randomly selected from the population living in the Nanoro HDSS cohort to (a) study the relation between vaccination and morbidity (including hemoglobin levels, subclinical malaria and stunting) (b) perform hemocytometry in order to determine reference values for that population and estimate the prevalence and causes of anemia, using reference values from other Sub-Sahara Africa countries and industrialized countries.

In a cross sectional study among a healthy population in the Nanoro HDSS cohort, hemocytometry will be performed in order to define normal values for that population. In addition, hemoglobin levels can be related to the presence of iron deficiency, thalassemia and malaria and be corrected for important confounding factors, such as the family income, family composition, distance to a healthcare center and vaccination status. This study will allow to assess simultaneously the normal range of hemoglobin values, the prevalence of (different causes of) anemia, the prevalence of subclinical malaria parasitemia, as well as the influence of (timepoint of) vaccination on all these issues. It is hypothized that early vaccination with live attenuated vaccines has a protective effect against malaria and other severe infectious diseases and will result in a better nutritional status, a higher hemoglobin level and a higher threshold of subclinical parasitemia. The protective effect of early vaccination with live attenuated vaccines may be due to the long-term modulation of the immune system through epigenetic changes causing a right balance between the pro- and anti-inflammatory responses. Such balance can be determined by ex-vivo stimulation of whole blood by a variety of stimuli, including Mycobacterium tuberculosis and lipopolysaccharide from Escherichia coli, followed by measurement of ex vivo cytokine production. Previous studies among healthy volunteers in the Netherlands have shown that BCG is indeed capable to induce epigenetic changes and influence immune response by influencing various pathways including through genetic variations in mTOR, HK2, PFKP, GLS, and GLUD1/2 (ref).

The new Sysmex analysers are not only capable to determine hemocytometry, but are at the same time capable to detect malaria parasites directly. Interestingly, not only the asexual stages of the parasites are detected but the gametocytes as well. This may be very important as gametocyte carriers are known to play a crucial role in malaria transmission. Gametocytes are presently detected by light microscopy or by PCR, however these techniques are limited; the sensitivity of light microscopy is relatively low and PCR is too complex to perform in most rural sub-Saharan African settings. The new Sysmex hematology analysers are easy to operate at low costs and may as such become an important tool for malaria elimination programs. No data are presently available about gametocyte density in Burkina Faso in a large population, nor is the lower level of detection of gametocytes using the sysmex analyzers known.

This research has four main objectives :

  1. To perform hemocytometry among a healthy rural Burkina Faso population selected from the Nanoro HDSS cohort, in order to determine reference values for that population.
  2. To perform hemocytometry among a healthy rural Burkina Faso population selected from the Nanoro HDSS cohort, in order to estimate the prevalence and causes of anemia, using reference values from other Sub-Sahara Africa (SSA) countries and industrialized countries.
  3. To study the relation between (timepoint of) vaccination and morbidity (including hemoglobin levels, subclinical malaria, bacterial infection and stunting) among a healthy rural Burkina Faso population selected from the Nanoro HDSS cohort. For this objective the population will be stratified by birth cohort.
  4. To perform ex-vivo whole blood stimulation to assess differences in immune response between patientgroups with a different vaccination status, within a healthy rural Burkina Faso population selected from the Nanoro HDSS cohort Seondary objectives
  5. To assess the detection limit of gametocyte carriages for the new series Sysmex hematology analyzers.
  6. To assess if Salmonella resides in blood as a reservoir for invasive infection among a rural Burkina Faso population selected from the Nanoro HDSS cohort.
Being tested
Venipuncture
Medical subject headings
Anemia, Malaria, Falciparum

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • VenipunctureOther

    1. Full blood count and leukocyte differentiation.
    2. Detection of malaria parasites and parasite differentiation to trophozoites, gametocytes and ringstages (XN-30)
    3. Detection of anemia, thallasemia and sickle cell anemia (XN-20)
    4. Ex-vivo stimulation of wholeblood with various stimuli. Read-out will be a spectrum of cytokines (ELISA)
    5. Circulating cytokines and inflammatory markers (ELIZA)
    6. DNA analysis to assess genetic variations determining pro- versus anti inflammatory response including mTOR, HK2, PFKP, GLS, and GLUD1/2.
    7. pan-Salmonella PCR
    8. Gametocyte PCR
Study groups in NCT03176719
Study groupRoleWhat they receive
Children of 1 years old200 healthy volunteers aged between 12 and 23 months
Receives: Other: Venipuncture
Children aged 2-4200 healthy volunteers aged between 24 and 59 months
Receives: Other: Venipuncture
Children aged 5 - 9200 healthy volunteers aged between 60 and 119 months
Receives: Other: Venipuncture
Children aged 10 - 14200 healthy volunteers aged between 120 and 179 months
Receives: Other: Venipuncture
Adults of 15 years and older200 healthy volunteers of 180 months or older
Receives: Other: Venipuncture

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Vaccination data

    Vaccination data as recorded on the vaccination card

    Measured: June 2017 - December 2017

  2. Nutritional status (Z-score or BMI)

    weight (kg), height (cm) and upperarm circumference (mm) leading to outcome measure on nutritional status: as appropriate Z-score or BMI

    Measured: June 2017 - December 2017

  3. History of disease

    Recorded history of disease according to the participants health card

    Measured: June 2017 - December 2017

  4. Immunological profile

    Cytokine levels, including IL-1b, IL-6, IL-10, IFN-gamma, TNF-alpha and IL-17, which will be assessed through ELISA. Measurement will be done on stimulated and unstimulated blood. Ex-vivo whole blood stimulation will be done with RPMI, LPS, MTB, Staphylococcus aureus, Candida albicans and Salmonella Typhimurium.

    Measured: June 2017 - December 2017

  5. Genetic immunological profile

    DNA analysis to assess genetic variations determining pro- versus anti inflammatory response including mTOR, HK2, PFKP, GLS, and GLUD1/2.

    Measured: June 2017 - December 2017

  6. subclinical parasitemia

    low level malaria infection detected by SYSMEX hematology analyzer XN - 30

    Measured: June 2017 - December 2017

  7. Anemia

    Differentiation of different forms of anemia using SYSMEX hematology analyzers XN -20 and XN - 30

    Measured: June 2017 - December 2017

  8. Reference values for hemocytometry in a healthy rural population from Burkina Faso

    Hemocytometry using SYSMEX hematology analyzers XN -20 and XN - 30

    Measured: June 2017 - December 2017

Secondary outcomes (1)
  1. Gametocyte PCR

    Gametocyte PCR on EDTA whole blood stored in RNA protect

    Measured: June 2017 - December 2017

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Jun 2017
  2. Study start17 Jun 2017
  3. Primary completion31 Oct 2017
  4. Study completion31 Dec 2018 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Ecologic or community
Time perspective
Cross-sectional
Enrolment
1,005 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03176719
Sponsor's protocol ID
2017-3339
Acronym
NOVAC
Status last verified
Aug 2018
First submitted
18 May 2017
Last updated
4 Sep 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Kabore B, Post A, Berendsen MLT, Diallo S, Lompo P, Derra K, Rouamba E, Jacobs J, Tinto H, de Mast Q, van der Ven AJ. Red blood cell homeostasis in children and adults with and without asymptomatic malaria infection in Burkina Faso. PLoS One. 2020 Nov 30;15(11):e0242507. doi: 10.1371/journal.pone.0242507. eCollection 2020.

    PubMed 33253198

Questions about this trial

What is this clinical trial studying?

An observational study of Vaccine Reaction and Anemia, run by Radboud University Medical Center at 1 site in Burkina Faso.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 4 Sep 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Burkina Faso. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Vaccination data (time frame: June 2017 - December 2017). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03176719, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in